Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Regina Garcia Delgado"'
Autor:
Pankit Vachhani, Andrew Perkins, John Mascarenhas, Haifa Kathrin Al-Ali, Jean-Jacques Kiladjian, Sonia Cerquozzi, Jaroslaw Dybko, Regina Garcia Delgado, Jesus Hernández Rivas, Holger Hebart, Zhuying Huang, Cecile Krejsa, Hope Qamoos, Jesse Mcgreivy, Wayne P. Rothbaum, Srdan Verstovsek, Alessandro Vannucchi
Publikováno v:
HemaSphere, Vol 7, p e05521ca (2023)
Externí odkaz:
https://doaj.org/article/261ee9a28228476d9e8db2a327ebc354
Autor:
Marc E. Rothenberg, Florence Roufosse, Stanislas Faguer, Gerald J. Gleich, Jonathan Steinfeld, Steven W. Yancey, Eleni Mavropoulou, Namhee Kwon, Gabriel Ricardo García, Adriana Sosso, Luis Wehbe, Anahí Yañez, Daniël Blockmans, Martti Anton Antila, Daniela Blanco, Sergio Grava, Marina Andrade Lima, Andreia Luisa Francisco Pez, Mohamed A. Hamidou, Jean-Emmanuel Kahn, Guillaume Lefévre, Knut Brockow, Peter M. Kern, Andreas J. Reiter, Bastian Walz, Tobias Welte, Fabrizio Pane, Alessandro M. Vannucchi, Ruth Cerino-Javier, Alfredo Gazca-Aguilar, Dante D. Hernández-Colín, Héctor Glenn Valdéz-López, Izabela R. Kupryś-Lipińska, Jacek Musial, Witold Prejzner, Eniko Mihaly, Viola Popov, Mihnea Tudor Zdrenghea, Sergey V. Gritsaev, Vladimir Ivanov, Nikolay Tsyba, Aránzazu Alonso, Maria Cinta Cid Xutgla, Maria Laura Fox, Regina Garcia Delgado, Jesús María Hernández Rivas, Guillermo Sanz Santillana, Ana Isabel González, Andrew J. Wardlaw, Praveen Akuthota, Joseph H. Butterfield, Geoffrey L. Chupp, John B. Cox, Devi Jhaveri
Publikováno v:
The Journal of Allergy and Clinical Immunology: In Practice. 10:2367-2374.e3
Autor:
Andrzej Lange, Jesús María Hernández-Rivas, Regina Garcia Delgado, John Mascarenhas, Jesse McGreivy, Venu Valmeekam, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Pankit Vachani, Anne Uyei, Alessandro M. Vannucchi, Cecile M. Krejsa, Wayne P. Rothbaum, Andrew C. Perkins, Srdan Verstovsek
Publikováno v:
Blood. 138:3581-3581
Introduction Patients (pts) with MF who discontinue ruxolitinib due to resistance or progression have a poor prognosis (median OS, 14 months; Kuykendall et al. Ann Hematol. 2018). Available therapies provide symptom control and reduce spleen volumes,
Autor:
Ana Triguero, Alexandra Pedraza, Manuel Pérez, María Isabel Mata, Beatriz Bellosillo, María Laura Fox, Montserrat Gómez, Regina Garcia-Delgado, Mercedes Gasior Kabat, Francisca Ferrer Marin, Valentín Garcia Gutierrez, Anna Angona, María Teresa Gómez-Casares, Beatriz Cuevas, Clara Martínez, Raul Perez Lopez, Jose Maria Raya Sanchez, Lucia Guerrero, Ilda Maria Murillo, Carlos Castillo, Cristina Sanz, Juan Carlos Hernandez Boluda, Alberto Alvarez-Larran
Publikováno v:
Blood. 138:3621-3621
Introduction: Current recommendations for patients with low-risk polycythemia vera (PV) include hematocrit (Htc) control with phlebotomies and primary prophylaxis of thrombosis with low-dose aspirin. There is scarce information regarding the hematolo
Autor:
Damaj Gandhi Laurent, John Mascarenhas, Alessandro M. Vannucchi, Hope Qamoos, Adam J. Mead, Regina Garcia-Delgado, Anne Uyei, Andrzej Pluta, Haifa Kathrin Al-Ali
Publikováno v:
Blood. 136:44-45
Background: Myelofibrosis (MF), which comprises primary MF (PMF), post-polycythemia vera MF (post-PV-MF), and post-essential thrombocythemia MF (post-ET-MF), is a clonal myeloproliferative neoplasm characterized by progressive bone marrow fibrosis, i
Autor:
Jason Gotlib, Nashat Y. Gabrail, Wayne Rothbaum, Regina Garcia-Delgado, Timothy Sbardellati, Jesse McGreivy, Casey O'Connell, Claire N. Harrison, Jean-Jacques Kiladjian
Publikováno v:
Blood. 134:4168-4168
Background: Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) characterized by clonal stem cell proliferation of the erythroid, myeloid, and megakaryocytic lines. The predominant clinical characteristic is an increase in red cell mass, re
Autor:
Srdan Verstovsek, László Rejtő, Joanne Ewing, Eric Jourdan, Marek Hus, Jesse McGreivy, Philipp J. Jost, Wayne Rothbaum, Sebastian Grosicki, Holger Hebart, Regina Garcia-Delgado, Andrzej Pluta, Donal P. McLornan, Haifa Kathrin Al-Ali, Irum Khan
Publikováno v:
Blood. 134:2945-2945
Background: Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by progressive bone marrow fibrosis, ineffective erythropoiesis, dysplastic megakaryocyte hyperplasia, and extramedullary hematopoiesis. MF includes primary MF (PMF),
Autor:
Moshe Mittelman, Dominik Selleslag, Uwe Platzbecker, Giuseppe Rossi, Achilles Anagnostopoulos, C. Denzlinger, Boris V. Afanasyev, Arnon Nagler, Benjamin Brenner, Raymond S.M. Wong, Regina Garcia-Delgado, Maria Socorro O Portella, Zewen Zhu, Sebastian Grosicki
Publikováno v:
The Lancet. Haematology. 5(1)
Summary Background Thrombocytopenia is a life-threatening complication in patients with advanced myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). In this study (ASPIRE), we aimed to assess eltrombopag, an oral thrombopoietin recepto
Autor:
María-Antonia Durán, Silvia García, Manuel Pérez-Encinas, J. M. Raya, Valentín García-Gutiérrez, María-Laura Fox, María-Isabel Mata-Vázquez, Juan-Gonzalo Correa, Alberto Alvarez-Larrán, Juan Carlos Hernández-Boluda, Ana Kerguelen, Manuel Albors, Francisco Cervantes, Joaquin Martinez-Lopez, Natalia Estrada, Regina Garcia-Delgado, Francisca Ferrer-Marín
Publikováno v:
EUROPEAN JOURNAL OF HAEMATOLOGY
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
European Journal of Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
European Journal of Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Objective Erythropoiesis-stimulating agents (ESAs) are commonly used to treat the anemia of myelofibrosis (MF), but information on the predictors of response is limited. Methods Results of ESA therapy were analyzed in 163 MF patients with severe anem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1ad287dacd9ba100545a671fcedfef9
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1414
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1414
Publikováno v:
Advances in therapy. 28
The management of myelodysplastic syndromes (MDS) in elderly patients is a significant clinical problem. The therapeutic options range from observation alone for patients with low-risk disease, lenalidomide for patients with 5q-syndrome, to 5-azacyti